Taro Yamanaka
@TaroY_oncology
Followers
205
Following
240
Media
21
Statuses
400
Medical oncologist 🇯🇵 | National Cancer Center Hospital, Japan | Breast, GYN, rare & GU cancers | All views my own.
Tokyo, Japan
Joined October 2023
In 2024 BMS ended the collaboration with Eisai to co-develop farletuzumab ecteribulin (FZEC, MORAb-202). Data from the two phase II studies sponsored by BMS have been released on https://t.co/bziUCK5aXS
https://t.co/ajDohzAx1r
https://t.co/SEm6KJC8FY 👇👇
2
3
8
#Collaborations are keys to success! A whirlwind trip to #NCCH and @Phase1_NCCH - meeting colleagues and friends from #Japan and beyond. We need to build upon this momentum to move our field forward together. Thanks again for your wonderful hospitality and exchange. @apoddc
0
4
14
Thanks @TaroY_oncology for the shout out! It was a real pleasure meeting you at the @Phase1_NCCH meeting. We need young oncologists like yourself to help drive our field forward as a team. @apoddc @CUHKMedicine #drugdevelopment
🌟My first time joining the NCCH Japan Workshop regarding Oncology Phase 1 Trials & TR! 🌏 As a young oncologist, it was inspiring to hear from global experts. 💬 It made me reflect on better strategies for Asia and Japan. @Phase1_NCCH @herbloong
#Oncology #EarlyPhaseTrials
0
2
4
🌟My first time joining the NCCH Japan Workshop regarding Oncology Phase 1 Trials & TR! 🌏 As a young oncologist, it was inspiring to hear from global experts. 💬 It made me reflect on better strategies for Asia and Japan. @Phase1_NCCH @herbloong
#Oncology #EarlyPhaseTrials
0
0
7
@DFCI_BreastOnc is leading a trial on the use of #ColdCaps in preventing #HairLoss with novel #BreastCancer therapies, including sacituzumab, eribulin, or trastuzumab deruxtecan. Contact us for info about the study or visit: https://t.co/18QCVsY6KR
#ScalpCooling; PI @esalehiDNP
dana-farber.org
This research is being done to compare rates of hair loss of people with metastatic breast who use scalp cooling versus those who do not use scalp cooling after receiving standard of care treatment...
1
6
14
いよいよ明日9:30から開催！ 「第7回 早期新薬開発試験 トランスレーショナルリサーチワークショップ」 最新TR研究、薬剤開発の最新事情から、米/英/香港の取組をしる機会。 🔽まだお申込み可能です！ぜひお気軽にご参加ください。 https://t.co/7ekguWWdfF
0
3
7
Check out this just published study in @ESMO_Open, led by Dr. Stefania Morganti (@StefiMorganti) looking at survival outcomes and the role of #DNADX #ctDNA testing in patients treated with #SacituzumabGovitecan for #MetastaticBreastCancer ** 🔓Open access article link is in the
1
5
13
The first, evidence-based ESMO-ESTRO consensus statements to guide the combination of RT with targeted cancer therapies and immunotherapy!!! They have expected that the toxicity of combining RT with ICIs is low, particularly for PD-(L)1 inhibitors. For most combinations with
2
61
148
Editorial: Comparative efficacy between 400-mg and 600-mg ribociclib doses in hormone receptor–positive breast cancer is clinically minimal, but differences in toxicity are significant. https://t.co/8jTn8oUW5K
3
21
48
Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Advanced #PenileCancer The Nonrandomized HERCULES (LACOG 0218) Clinical Trial https://t.co/93oooimaq3 The phase 2 HERCULES (LACOG 0218) trial evaluated pembrolizumab combined with platinum-based chemotherapy as
0
11
39
🚨 HRD score isn’t enough—can genomics unlock smarter PARPi use in ovarian cancer? 🧬 🧾 Study (IJGC, n=221, Chinese OC cohort) 🔍 Genomic profiling + HRD cutoff ≥39 📊 Key biomarkers → longer PFS ✨ BRCA mutations ✨ High indel burden ✨ High LOH ✨ Clonal mutations 🧪 New
2
17
47
Access to novel cancer medicines in Europe: inequities across countries and their drivers - ESMO Open @myESMO
esmoopen.com
An increasing number of cancer medicines are being developed and approved. Access to these medicines is important for improving patient outcomes and overall quality of care, yet achieving equitable...
0
11
23
eVERA press release: Giredestrant (oral SERD) + everolimus improved PFS in ITT and ESR1m c/w ET + everolimus in pts w/ prior CDK4/6i w/ HR+ MBC! Great news for pts! @elmayermd @DFCI_BreastOnc @genentech
https://t.co/vwiEQqVUEN
businesswire.com
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III evERA study evaluating investigation...
3
19
57
FDA approves pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection https://t.co/WCWJtKqeHh On September 19, 2025, the FDA approved pembrolizumab and berahyaluronidase alfa-pmph as a subcutaneous formulation for adult and pediatric patients (≥12 years)
0
19
35
NCI Cancer Center Joint Statement on the importance and safety of HPV vaccines at preventing HPV related cancers. No one with a cervix should die from cervix cancer in this country - utterly no excuse
0
6
14
Tumor lysis syndrome has evolved and become less predictable with the introduction of new cancer therapies. A new review explores risk factors and causes of the syndrome, as well as strategies for treatment and prevention. Learn more in the Review Article “Tumor Lysis Syndrome”
2
109
381
Communication about health after cancer is critical for AYA survivors. This review draws on AYAs’ and families’ lived experiences to assess clinician practices and share recommendations. https://t.co/bjgjHHqa0g
@AbbyRosenbergMD @LCHeathcote @l_schapira @OncoAlert #AYACSM
2
11
26
🆕article in press: Impact of anthracyclines in genomic high risk, node-negative, HR-positive/HER2-negative breast cancer @fredhow
https://t.co/j6Y2eiaxvr
0
12
26
The rising tides of cancers among young adults in @ESMO_Open. Global rise in early-onset cancers among young adults. This growing trend is a critical scientific challenge requiring an urgent comprehensive in-depth investigation. https://t.co/42MWp1j1xF
1
18
34